Bayer AG disclosed Monday that it received a subpoena from the U.S. attorney for New Jersey relating to its withdrawn Baycol/Cerivastatin anti-cholesterol drug, which has allegedly been linked to about 100 deaths.
Bayer received the subpoena last month, according to the company’s annual report filed with the federal Securities and Exchange Commission.
The German-based pharmaceutical and chemical company had received a subpoena in January 2004 also related to its Baycol drug from the Defense Criminal Investigative Service of the U.S. Department of Defense Inspector General.
Bayer withdrew Baycol from the market in August 2001 after it was allegedly linked to about 100 deaths.
The company said that as of Jan. 13, it had paid $1.15 billion to settle 3,082 Baycol cases, without acknowledging any liability.